Hydrochlorothiazide; labetalol hydrochloride - Generic Drug Details

What are the generic drug sources for hydrochlorothiazide; labetalol hydrochloride and what is the scope of freedom to operate?

Hydrochlorothiazide; labetalol hydrochloride is the generic ingredient in two branded drugs marketed by Schering and Glaxosmithkline, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for hydrochlorothiazide; labetalol hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Clinical Trials:	1
DailyMed Link:	hydrochlorothiazide; labetalol hydrochloride at DailyMed

Recent Clinical Trials for hydrochlorothiazide; labetalol hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
VA Office of Research and Development
US Department of Veterans Affairs

See all hydrochlorothiazide; labetalol hydrochloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for hydrochlorothiazide; labetalol hydrochloride

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C07AG	Alpha and beta blocking agents
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for hydrochlorothiazide; labetalol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-003	Apr 10, 1987		DISCN	No	No
Schering	NORMOZIDE	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019046-004	Apr 6, 1987		DISCN	No	No
Schering	NORMOZIDE	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019046-003	Apr 6, 1987		DISCN	No	No
Schering	NORMOZIDE	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019046-001	Apr 6, 1987		DISCN	No	No
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-002	Apr 10, 1987		DISCN	No	No
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-001	Apr 10, 1987		DISCN	No	No

Expired US Patents for hydrochlorothiazide; labetalol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-004	Apr 10, 1987	4,066,755
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-002	Apr 10, 1987	4,066,755
Schering	NORMOZIDE	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019046-001	Apr 6, 1987	4,012,444
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-001	Apr 10, 1987	4,066,755
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-003	Apr 10, 1987	4,012,444
Schering	NORMOZIDE	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019046-003	Apr 6, 1987	4,066,755

Market Dynamics and Financial Trajectory for Hydrochlorothiazide and Labetalol Hydrochloride

Last updated: February 19, 2026

What is the current market size for Hydrochlorothiazide and Labetalol Hydrochloride?

Hydrochlorothiazide (HCTZ) and Labetalol Hydrochloride are widely used antihypertensive agents. The global market for these medications is primarily driven by increasing prevalence of hypertension and cardiovascular diseases.

• Hydrochlorothiazide: Valued at approximately USD 1.2 billion in 2022, with a compound annual growth rate (CAGR) estimated at 2.8% from 2023 to 2028.
• Labetalol Hydrochloride: Valued at around USD 410 million in 2022, growing at a CAGR of 3.2% over the same period.

Market Breakdown:	Drug	2022 Valuation (USD million)	Projected CAGR (2023–2028)	2028 Estimate (USD million)
Hydrochlorothiazide	1,200	2.8%	1,385
Labetalol Hydrochloride	410	3.2%	480

These estimates derive from industry reports (e.g., Research and Markets, 2023).

What are the key drivers influencing market growth?

• Rising prevalence of hypertension: Globally, the number of adults with high blood pressure exceeds 1.3 billion, fueling demand.
• Aging populations: Elderly populations are more susceptible to hypertension, increasing prescription rates.
• Increased cardiovascular disease awareness: Enhanced screening and public health policies raise the use of antihypertensives.
• Availability of generic formulations: Cost competitiveness of generics sustains demand, especially in emerging markets.

What are the primary market challenges?

• Patent expirations: Many formulations of Hydrochlorothiazide have lost patent protection, leading to increased generic competition.
• Side-effect profiles: Hydrochlorothiazide's association with electrolyte imbalance discourages use in some patient populations.
• Regulatory hurdles: Tightening regulations on drug labels and manufacturing practices can delay product approvals and market entry.

How does patent status influence future revenues?

• Hydrochlorothiazide: Multiple patents expired in the last decade; generics dominate, constraining revenue growth for branded manufacturers.
• Labetalol Hydrochloride: The original patent expired in 2008; current revenues depend on regional formulations and market penetration of generics.

What are the R&D prospects and pipeline developments?

No significant new chemical entities (NCEs) targeting Hydrochlorothiazide or Labetalol Hydrochloride are currently in advanced clinical trials. Focus shifts to combination therapies, extended-release formulations, and biosimilars.

How do regional variations affect market dynamics?

• United States: Dominates with USD 600 million annual sales for Hydrochlorothiazide, driven by high hypertension prevalence and insurance coverage.
• Europe: Slightly slower growth; healthcare reforms and stricter regulation influence market size.
• Emerging Markets: Rapid expansion due to increasing healthcare access, with India and China showing the highest growth rates (CAGR 4.5–6%).

What are financial outlooks based on historical data and projections?

Item	2022 ($ million)	2023 Estimate	2024 Projection	2025 Projection
Global Market Size	1,610	1,680	1,770	1,860
Revenue from Hydrochlorothiazide	1,200	1,250	1,310	1,380
Revenue from Labetalol Hydrochloride	410	430	450	470

Note: Growth driven mainly by increased prescribing in emerging markets and aging populations.

Key market players and competitive landscape

Major pharmaceutical companies in this space include:

• AstraZeneca
• Novartis
• Mylan (now part of Viatris)
• Teva Pharmaceuticals
• Sun Pharma

The market is highly fragmented with several regional generics manufacturers.

Critical regulatory considerations

• Regulatory agencies (FDA, EMA, PMDA) enforce strict standards for manufacturing, especially for generics.
• Label updates, bioequivalence requirements, and quality control measures impact market entry timelines.
• Recent regulations prioritize safety profiles; Hydrochlorothiazide’s association with metabolic disturbances has prompted label revisions.

---

Key Takeaways

• The market for Hydrochlorothiazide and Labetalol Hydrochloride is growing modestly, with a combined valuation expected to reach USD 1.86 billion by 2025.
• Patent expirations have shifted revenue largely to generic manufacturers, constraining growth for branded drugs.
• Regional differences influence market sizes, with the US leading and emerging markets showing higher growth rates.
• R&D is limited; future prospects focus on combination products and formulations.
• Regulatory policies remain critical for market access, especially for generics.

FAQs

Q1: Which regions offer the highest growth potential for Hydrochlorothiazide?
Emerging markets like India and China forecast CAGR of 4.5–6%, driven by increasing hypertension prevalence and expanding healthcare infrastructure.

Q2: How do patent expirations affect market competition?
Patents expired over a decade ago; generic versions dominate sales, leading to price pressure and narrower margins for brand-name producers.

Q3: Are there any new formulations in development?
Current focus centers on combination therapies and controlled-release formulations, with no significant NCEs in advanced clinical stages.

Q4: What are the main regulatory risks?
Regulatory bodies require rigorous bioequivalence data, and label updates may impose additional manufacturing or safety standards impacting commercialization.

Q5: How does drug safety impact market sustainability?
Hydrochlorothiazide’s potential metabolic side effects have prompted regulatory label updates, influencing prescribing practices and market stability.

---

References

1. Research and Markets. (2023). Global antihypertensive drugs market report.
2. IQVIA. (2022). Pharmaceutical market analysis.
3. U.S. Food and Drug Administration. (2022). Drug approvals and safety updates.
4. European Medicines Agency. (2022). Regulatory guidance for antihypertensive drugs.